Perspectives of differentiation therapies of acute myeloid leukemia: The search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin D and vitamin D analogs

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Marchwicka, Aleksandra ^a   Cebrat, Małgorzata ^b   Sampath, Preetha ^a   Śniezewski, Łukasz ^b   Marcinkowska, Ewa ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

All trans retinoic acid; Cancer; Differentiation; Exon; Gene; Leukemia; Vitamin D receptor

Indexed keywords

ALFACALCIDOL; ALPHA INTERFERON; ARSENIC TRIOXIDE; CALCITRIOL; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN EPSILON; CD135 ANTIGEN; CYTARABINE; HISTONE DEACETYLASE; HYDROXYUREA; IDARUBICIN; ISOTRETINOIN; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; NUCLEOPHOSMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; STAT5B PROTEIN; UNINDEXED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLAST CELL; CANCER PATIENT; CELL DIFFERENTIATION; CELL NUCLEUS INCLUSION BODY; CYTOGENETICS; EX VIVO STUDY; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

EID: 84904650742     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00125     Document Type: Review

References (163)

1. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi: 10.1016/j.cell.2011.02.013
2. Sawyers C. Targeted cancer therapy. Nature (2004) 432:294-7. doi:10.1038/nature03095
3. Hannun Y. Apoptosis and the dilemma of cancer chemotherapy. Blood (1997) 89:1845-53.
4. Tenen D. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer (2003) 3:89-101. doi:10.1038/nrc989
5. Sachs L. Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Res (1987) 47:1981-6.
6. Breitman T, Selonick S, Collins S. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A (1980) 77:2936-40. doi:10.1073/pnas.77.5.2936
7. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72:567-72.
8. Tallman M, Nabhan C, Feusner J, Rowe J. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood (2002) 99:759-67. doi:10.1182/blood.V99.3.759
9. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 66:675-84. doi:10.1016/0092-8674(91)90113-D
10. Kakizuka A, Miller WJ, Umesono K, Warrell RJ, Frankel S, Murty V, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 66:663-74. doi:10.1016/0092-8674(91)90112-C
11. Redner R. Variations on a theme: the alternate translocations in APL. Leukemia (2002) 16:1927-32. doi:10.1038/sj.leu.2402720
12. Rego E, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner R, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene (2006) 25:1974-9. doi:10.1038/sj.onc.1209216
13. Collins S. Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol (2008) 15:346-51. doi:10.1097/MOH.0b013e3283007edf
14. Mark M, Chambon P. Functions of RARs and RXRs in vivo: genetic dissection of the retinoid signaling pathway. Pure Appl Chem (2003) 75:1709-32. doi:10.1351/pac200375111709
15. Robertson K, Emami B, Collins S. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood (1992) 80:1885-9.
16. Iwasaki H, Somoza C, Shigematsu H, Duprez E, Iwasaki-Arai J, Mizuno S, et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 106:1590-600.
17. Mueller B, Pabst T, Fos J, Petkovic V, Fey M, Asou N, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood (2006) 107:3330-8. doi:10.1182/blood-2005-07-3068
18. Duprez E, Wagner K, Koch H, Tenen D. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J (2003) 22:5806-16. doi:10.1093/emboj/cdg556
19. Morosetti R, Park D, Chumakov A, Grillier I, Shiohara M, Gombart A, et al. A novel, myeloid transcription factor, C/EBPepsilon, is upregulated during granulocytic, but not monocytic, differentiation. Blood (1997) 90:2591-600.
20. Bernardi R, Pandolfi P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 8:1006-16. doi:10.1038/nrm2277
21. Daniel M, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 82:1858-67.
22. Lallemand-Breitenbach V, de Thé H. PML nuclear bodies. Cold Spring Harb Perspect Biol (2010) 2:a000661. doi:10.1101/cshperspect.a000661
23. Carracedo A, Ito K, Pandolfi P. The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol (2011) 23:360-6. doi:10.1016/j.ceb.2011.03.011
24. Saeed S, Logie C, Stunnenberg H, Martens J. Genome-wide functions of PML-RARα in acute promyelocytic leukaemia. Br J Cancer (2011) 104:554-8. doi:10.1038/sj.bjc.6606095
25. Khalfin-Rabinovich Y, Weinstein A, Levi B-Z. PML is a key component for the differentiation of myeloid progenitor cells to macrophages. Int Immunol (2011) 23:287-96. doi:10.1093/intimm/dxr004
26. Raelson J, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 88:2826-32.
27. Melnick A, Licht J. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 93:3167-215.
28. Sirulnik A, Melnick A, Zelent A. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol (2003) 16:387-408. doi:10.1016/S1521-6926(03)00062-8
29. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 10:775-83. doi:10.1038/nrc2943
30. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol (2013) 97:717-25. doi:10.1007/s12185-013-1354-4
31. Rego E, Pandolfi P. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol (2001) 38:54-70. doi:10.1053/shem.2001.20865
32. Salomoni P, Ferguson B, Wyllie A, Rich T. New insights into the role of PML in tumour suppression. Cell Res (2008) 18:622-40. doi:10.1038/cr.2008.58
33. Gurrieri C, Nafam K, Merghoub T, Bernardi R, Capodieci P, Biondi A, et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood (2004) 103:2358-62. doi:10.1182/blood-2003-07-2200
34. Bellodi C, Kindle K, Bernassola F, Dinsdale D, Cossarizza A, Melino G, et al. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem (2006) 281:14465-73. doi:10.1074/jbc.M600457200
35. Tsukada J, Yoshida Y, Kominato Y, Auron P. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine (2011) 54:6-19. doi:10.1016/j.cyto.2010.12.019
36. Scott L, Civin C, Rorth P, Friedman A. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood (1992) 80:1725-35.
37. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem (1998) 273:29279-82. doi:10.1074/jbc.273.45.29279
38. Johansen L, Iwama A, Lodie T, Sasaki K, Felsher D, Golub T, et al. c-Myc is a critical target for C/EBPalpha in granulopoiesis. Mol Cell Biol (2001) 21(11):3789-806. doi:10.1128/MCB.21.11.3789-3806.2001
39. Lekstrom-Himes J. The role of C/EBPepsilon in the terminal stages of granulocyte differentiation. Stem Cells (2001) 19:125-33. doi:10.1634/stemcells.19-2-125
40. Tavor S, Park D, Gery S, Vuong P, Gombart A, Koeffler H. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem (2003) 278:52651-9. doi:10.1074/jbc.M307077200
41. Marcinkowska E, Wang X, Studzinski G. C/EBPβ: a candidate for a major player in vitamin D-induced monocytic differentiation of human leukemia cells. In: Stolzt V, editor. Vitamin D: New Research. New York, NY: Nova Science Publishers, Inc. (2006). p. 25-40.
42. Friedman A. C/EBPalpha induces PU.1 and interacts with AP-1 and NF-kappaB to regulate myeloid development. Blood Cells Mol Dis (2007) 39:340-3. doi:10.1016/j.bcmd.2007.06.010
43. Kamashev D, Vitoux D, de Thé H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med (2004) 199:1163-74. doi:10.1084/jem.20032226
44. Zhu J, Nasr R, Pérès L, Riaucoux-Lormière F, Honoré N, Berthier C, et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell (2007) 12:23-35. doi:10.1016/j.ccr.2007.06.004
45. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, et al. AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor. Cancer Res (2002) 62:7050-8.
46. Gianni M, Ponzanelli I, Mologni L, Reichert U, Rambaldi A, Terao M, et al. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ (2000) 7:447-60. doi:10.1038/sj.cdd.4400673
47. Cai X, Shen Y, Zhu Q, Jia P, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia (2000) 14:262-70. doi:10.1038/sj.leu.2401650
48. Chen Z, Chen G, Shen Z, Chen S, Wang Z. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol (2001) 38:26-36. doi:10.1053/shem.2001.20863
49. Chen Z, Wang Z, Chen S. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther (1997) 76:141-9. doi:10.1016/S0163-7258(97)00090-9
50. Li J, Chen P, Sinogeeva N, Gorospe M, Wersto R, Chrest F, et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem (2002) 277:49504-10. doi:10.1074/jbc.M207836200
51. de Thé H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 198:11-21. doi:10.1083/jcb.201112044
52. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A (1999) 96:14807-12. doi:10.1073/pnas.96.26.14807
53. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, et al. Role of promyelocytic leukemia (PML) sumoylation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 193:1361-71. doi:10.1084/jem.193.12.1361
54. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell (2010) 18:88-98. doi:10.1016/j.ccr.2010.06.003
55. Isakson P, Bjørås M, Bøe S, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood (2010) 116:2324-31. doi:10.1182/blood-2010-01-261040
56. Wang Z, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 111:2505-15. doi:10.1182/blood-2007-07-102798
57. Hillestad L. Acute promyelocytic leukemia. Acta Med Scand (1957) 159:189-94. doi:10.1111/j.0954-6820.1957.tb00124.x
58. Warrell RP Jr, Frankel S, Miller WH Jr, Scheinberg D, Itri L, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 324:1385-93.
59. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood (1997) 90:1014-21.
60. Shen Y, Shen Z, Yan H, Chen J, Zeng X, Li J, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia (2001) 15:735-41. doi:10.1038/sj.leu.2402106
61. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 369:111-21. doi:10.1056/NEJMoa1300874
62. Lo-Coco F, Cicconi L. What is the standard regimen for patients with acute promyelocytic leukemia? Curr Hematol Malig Rep (2014). doi:10.1007/s11899-014-0206-5
63. Petrie K, Zelent A. AML1/ETO, a promiscuous fusion oncoprotein. Blood (2007) 109:4109-10. doi:10.1182/blood-2007-02-075804
64. Elagib K, Goldfarb A. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett (2007) 251:179-86. doi:10.1016/j.canlet.2006.10.010
65. Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer A. Multiple regions of ETO cooperate in transcriptional repression. J Biol Chem (2001) 276:9889-95. doi:10.1074/jbc.M010582200
66. Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L, et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood (2007) 109:4432-40. doi:10.1182/blood-2006-09-045781
67. Bots M, Verbrugge I, Martin B, Salmon J, Ghisi M, Baker A, et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood (2014) 123:1341-52. doi:10.1182/blood-2013-03-488114
68. Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391:815-8. doi:10.1038/35901
69. Minucci S, Nervi C, Lo Coco F, Pelicci P. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 20:3110-5. doi:10.1038/sj.onc.1204336
70. Konopleva M, Elstner E, McQueen T, Tsao T, Sudarikov A, Hu W, et al. Peroxisome proliferator-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther (2004) 3:1249-62.
71. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 4:61-70. doi:10.1038/nrc1254
72. Moon R, Kohn A, de Ferrari G, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 5:691-701. doi:10.1038/nrg1427
73. Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N, et al. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol (1999) 15:1027-58.
74. Tontonoz P, Nagy L, Alvarez J, Thomazy V, Evans R. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 93:241-52. doi:10.1016/S0092-8674(00)81575-5
75. Rowe A. Retinoid X receptors. Int J Biochem Cell Biol (1997) 29:275-8. doi:10.1016/S1357-2725(96)00101-X
76. Tsai D, Luger S, Andreadis C, Vogl D, Kemner A, Potuzak M, et al. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res (2008) 14:5619-25. doi:10.1158/1078-0432.CCR-07-5185
77. Dusso A, Brown A, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol (2005) 289:F8-28. doi:10.1152/ajprenal.00336.2004
78. Mithal A, Wahl D, Bonjour J, Burckhardt P, Dawson-Hughes B, Eisman J, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int (2009) 20:1807-20. doi:10.1007/s00198-009-0954-6
79. Kragballe K. Vitamin D3 and skin diseases. Arch Dermatol Res (1992) 284(Suppl 1):S30-6. doi:10.1007/BF00638238
80. O'Kelly J, Histake J, Histake Y, Bishop J, Norman A, Koeffler H. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest (2002) 109:1091-9. doi:10.1172/JCI200212392
81. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol (2005) 97:93-101. doi:10.1016/j.jsbmb.2005.06.002
82. Okamoto R, Akagi T, Koeffler H. Vitamin D compounds and myelodysplastic syndrome. Leuk Lymphoma (2008) 49:12-3. doi:10.1080/10428190701757827
83. O'Neill J, Feldman S. Vitamin D analogue-based therapies for psoriasis. Drugs Today (2010) 46:351-60. doi:10.1358/dot.2010.46.5.1473264
84. Welsh J, Wietzke J, Zinser G, Smyczek S, Romu S, Tribble E, et al. Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol (2002) 83:85-92. doi:10.1016/S0960-0760(02)00277-7
85. Brown A, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med (2008) 29:433-52. doi:10.1016/j.mam.2008.04.001
86. Ma Y, Trump D, Johnson C. Vitamin D in combination cancer treatment. J Cancer (2010) 1:101-7. doi:10.7150/jca.1.101
87. Mehta A, Kumaran T, Marsh G, McCarthy D. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet (1984) 2(8405):761. doi:10.1016/S0140-6736(84)92676-X
88. Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, et al. 1 Alpha,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun (1981) 102:937-43. doi:10.1016/0006-291X(81)91628-4
89. Kim M, Mirandola L, Pandey A, Nguyen D, Jenkins M, Turcel M, et al. Application of vitamin D and derivatives in hematological malignancies. Cancer Lett (2012) 319:8-22. doi:10.1016/j.canlet.2011.10.026
90. Baurska H, Klopot A, Kielbinski M, Chrobak A, Wijas E, Kutner A, et al. Structure-function analysis of vitamin D2 analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation. J Steroid Biochem Mol Biol (2011) 126:46-54. doi:10.1016/j.jsbmb.2011.04.006
91. McDonnell D, Scott R, Kerner S, O'Malley B, Pike J. Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. Mol Endocrinol (1989) 3:635-44. doi:10.1210/mend-3-4-635
92. Kahlen J, Carlberg C. Identification of a vitamin D receptor homodimer-type response element in the rat calcitriol 24-hydroxylase gene promoter. Biochem Biophys Res Commun (1994) 202:1366-72. doi:10.1006/bbrc.1994.2081
93. Vaisanen S, Dunlop T, Sinkkonen L, Frank C, Carlberg C. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-dihydroxyvitamin D3. J Mol Biol (2005) 350:65-77. doi:10.1016/j.jmb.2005.04.057
94. Wang X, Wang T-T, White J, Studzinski G. Induction of kinase suppressor of RAS-1(KSR-1) gene by 1,25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 50-flanking region. Oncogene (2006) 25:7078-85. doi:10.1038/sj.onc.1209697
95. Cheng H, Chen J, Huang Y, Chang H, Hung W. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem (2006) 98:1450-6. doi:10.1002/jcb.20780
96. Carlberg C, Seuter S, de Mello V, Schwab U, Voutilainen S, Pulkki K, et al. Primary vitamin D target genes allow a categorization of possible benefits of vitamin D3 supplementation. PLoS One (2013) 8(7):e71042. doi:10.1371/journal.pone.0071042
97. Marcinkowska E, Wiedlocha A, Radzikowski C. 1,25-Dihydroxyvitamin D3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem Biophys Res Commun (1997) 241:419-26. doi:10.1006/bbrc.1997.7832
98. Hughes P, Brown G. 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway. J Cell Biochem (2006) 98:590-617. doi:10.1002/jcb.20787
99. Marcinkowska E, Wiedlocha A, Radzikowski C. Evidence that phosphatidylinositol 3-kinase and p70S6K protein are involved in differentiation of HL-60 cells induced by calcitriol. Anticancer Res (1998) 18:3507-14.
100. Hmama Z, Nandan D, Sly L, Knutson K, Herrera-Velit P, Reiner N. 1Alpha,25-dihydroxyvitamin D3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med (1999) 190:1583-94. doi:10.1084/jem.190.11.1583
101. Ma Y, Trump D, Johnson C. Vitamin D and acute myeloid leukemia. J Cancer (2010) 3:101-7. doi:10.7150/jca.1.101
102. Trump D, Deeb K, Johnson C. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (2010) 16:1-9. doi:10.1097/PPO.0b013e3181c51ee6
103. Marcinkowska E, Garay E, Gocek E, Chrobak A, Wang X, Studzinski G. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp Cell Res (2006) 312:2054-65. doi:10.1016/j.yexcr.2006.03.003
104. Brown G, Choudhry M, Durham J, Drayson M, Michell R. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp Cell Res (1999) 253:511-8. doi:10.1006/excr.1999.4660
105. Rots N, Iavarone A, Bromleigh V, Freedman L. Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood (1999) 93:2721-9.
106. Suzuki T, Koyama Y, Hayakawa S, Munakata H, Isemura M. 1,25-Dihydroxyvitamin D3 suppresses exportin expression in human promyelocytic leukemia HL-60 cells. Biomed Res (2006) 27:89-92.
107. Suzuki T, Koyama Y, Ichikawa H, Tsushima K, Abe K, Hayakawa S, et al. 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct (2005) 30:1-6. doi:10.1247/csf.30.1
108. Hellström E, Robèrt K, Gahrton G, Mellstedt H, Lindemalm C, Einhorn S, et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol (1988) 40:449-59. doi:10.1111/j.1600-0609.1988.tb00855.x
109. Irino S, Taoka T. Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 [1 alpha(OH)D3]. Gan To Kagaku Ryoho (1988) 15:1183-90.
110. Nakayama S, Ishikawa T, Yabe H, Nagai K, Kasakura S, Uchino H. Successful treatment of a patient with acute myeloid leukemia with 1 alpha(OH)D3. Nihon Ketsueki Gakkai Zasshi (1988) 51:1026-30.
111. Takahashi T, Ichiba S, Okuno Y, Sugiyama H, Sakai Y, Imura H, et al. Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders. Rinsho Ketsueki (1989) 30:1-10.
112. Hellström E, Robèrt K, Samuelsson J, Lindemalm C, Grimfors G, Kimby E, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol (1990) 45:255-61. doi:10.1111/j.1600-0609.1990.tb00470.x
113. Petrini M, Caracciolo F, Corini M, Valentini P, Sabbatini A, Grassi B. Low-dose ARA-C and 1(OH)D3 administration in acute non lymphoid leukemia: pilot study. Haematologica (1991) 76:200-3.
114. Petrini M, Dastoli G, Valentini P, Mattii L, Trombi L, Testi R, et al. Synergistic effects of alpha interferon and 1,25 dihydroxyvitamin D3: preliminary evidence suggesting that interferon induces expression of the vitamin receptor. Haematologica (1991) 76:467-71.
115. Slapak C, Desforges J, Fogaren T, Miller K. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol (1992) 41:178-83. doi:10.1002/ajh.2830410307
116. Ferrero D, Campa E, Dellacasa C, Campana S, Foli C, Boccadoro M. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica (2004) 89:619-20.
117. Harrison J, Bershadskiy A. Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature. Leuk Res Treatment (2012) 125814:8. doi:10.1155/2012/125814
118. Jones G. Vitamin D analogs. Endocrinol Metab Clin North Am (2010) 39:447-72. doi:10.1016/j.ecl.2010.02.003
119. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int (2011) 79:702-7. doi:10.1038/ki.2010.387
120. Beer T, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res (2006) 26:2647-51.
121. Wietrzyk J, Nevozhay D, Milczarek M, Filip B, Kutner A. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol (2008) 62:787-97. doi:10.1007/s00280-007-0666-6
122. Peehl D, Seto E, Feldman D. Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. Urology (2001) 58:123-6. doi:10.1016/S0090-4295(01)01254-7
123. Peehl D, Seto E, Hsu J, Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol (2002) 168:1583-8. doi:10.1097/00005392-200210010-00089
124. Muindi J, Yu W, Ma Y, Engler K, Kong R, Trump D, et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology (2010) 151:4301-12. doi:10.1210/en.2009-1156
125. Anderson M, Nakane M, Ruan X, Kroeger P, Wu-Wong J. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol (2006) 57:234-40. doi:10.1007/s00280-005-0059-7
126. Horváth H, Khabir Z, Nittke T, Gruber S, Speer G, Manhardt T, et al. CYP24A1 splice variants - implications for the antitumorigenic actions of 1,25-(OH)2D3 in colorectal cancer. J Steroid Biochem Mol Biol (2010) 121:76-9. doi:10.1016/j.jsbmb.2010.03.080
127. Höbaus J, Hummel D, Thiem U, Fetahu I, Aggarwal A, Müllauer L, et al. Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer (2013) 133:1380-8. doi:10.1002/ijc.28143
128. Smith D, Johnson C, Freeman C, Muindi J, Wilson J, Trump D. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res (1999) 5:1339-45.
129. Beer T, Munar M, Henner W. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer (2001) 91:2431-9. doi:10.1002/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3
130. Muindi J, Peng Y, Potter D, Hershberger P, Tauch J, Capozzoli M, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther (2002) 72:648-59. doi:10.1067/mcp.2002.129305
131. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 33:451-8. doi:10.1111/j.1365-2141.1976.tb03563.x
132. Vardiman J, Harris N, Brunning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100:2292-302.
133. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program (2008) 2008:1-11. doi:10.1182/asheducation-2008.1.1
134. Sanders M, Valk P. The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol (2013) 20:79-85. doi:10.1097/MOH.0b013e32835d821c
135. Kuhnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol (2012) 96(2):153-63. doi:10.1007/s12185-012-1123-9
136. Falini B, Nicoletti I, Bolli N, Martelli M, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica (2007) 92:519-32. doi:10.3324/haematol.11007
137. Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci (2013) 22:545-56. doi:10.1002/pro.2240
138. Reilly J. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev (2003) 17:241-8. doi:10.1016/S0268-960X(03)00024-9
139. Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood (2010) 116:354-65. doi:10.1182/blood-2009-11-254441
140. Gocek E, Kielbinski M, Baurska H, Haus O, Kutner A, Marcinkowska E. Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations. Leuk Res (2010) 34:649-57. doi:10.1016/j.leukres.2009.10.004
141. Baurska H, Kiełbinski M, Biecek P, Haus O, Jazwiec B, Kutner A, et al. Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia. Leuk Res (2014) 38:638-47. doi:10.1016/j.leukres.2014.03.009
142. Quentmeier H, Reinhardt J, Zaborski M, Drexler H. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia (2003) 17:120-4. doi:10.1038/sj.leu.2402740
143. Gocek E, Marchwicka A, Bujko K, Marcinkowska E. NADPH-cytochrome p450 reductase is regulated by all-trans retinoic acid and by 1,25-dihydroxyvitamin D3 in human acute myeloid leukemia cells. PLoS One (2014) 9:e91752. doi:10.1371/journal.pone.0091752
144. Marcinkowska E, Kutner A, Radzikowski C. Cell differentiating and anti-proliferative activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol (1998) 67:71-8. doi:10.1016/S0960-0760(98)00065-X
145. Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res (1996) 56:3570-6.
146. Elstner E, Linker-Israeli M, Le J, Umiel T, Michl P, Said J, et al. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J Clin Invest (1997) 99:349-60. doi:10.1172/JCI119164
147. Doré B, Uskokovíc M, Momparler R. Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. Leuk Res (1993) 17:749-57. doi:10.1016/0145-2126(93)90108-W
148. Defacque H, Piquemal D, Basset A, Marti J, Commes T. Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J Cell Physiol (1999) 178:109-19. doi:10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.0.CO;2-X
149. Munker R, Norman A, Koeffler H. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest (1986) 78:424-30. doi:10.1172/JCI112593
150. Gocek E, Marchwicka A, Baurska H, Chrobak A, Marcinkowska E. Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. J Steroid Biochem Mol Biol (2012) 132:220-6. doi:10.1016/j.jsbmb.2012.07.001
151. Douer D, Koeffler H. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest (1982) 69:277-83. doi:10.1172/JCI110450
152. Baker A, McDonnell D, Hughes M, Crisp T, Mangelsdorf D, Haussler M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A (1988) 85:3294-8. doi:10.1073/pnas.85.10.3294
153. Miyamoto K, Kesterson R, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol (1997) 11:1165-79. doi:10.1210/mend.11.8.9951
154. Jurutka P, Remus L, Whitfield G, Thompson P, Hsieh J-C, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol (2000) 14:401-20. doi:10.1210/me.14.3.401
155. van Etten E, Verlinden L, Giulietti A, Ramos-Lopez E, Branisteanu D, Ferreira G, et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol (2007) 37:395-405. doi:10.1002/eji.200636043
156. Crofts L, Hancock M, Morrison N, Eisman J. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA (1998) 95:10529-34. doi:10.1073/pnas.95.18.10529
157. Sunn K, Cock T, Crofts L, Eisman J, Gardiner E. Novel N-terminal variant of human VDR. Mol Endocrinol (2001) 15:1599-609. doi:10.1210/me.15.9.1599
158. Gardiner E, Esteban L, Fong C, Allison S, Flanagan J, Kouzmenko A, et al. Vitamin D receptor B1 and exon 1d: functional and evolutionary analysis. J Steroid Biochem Mol Biol (2004) 8(9-90):233-8. doi:10.1016/j.jsbmb.2004.03.078
159. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res (1999) 14:240-7. doi:10.1359/jbmr.1999.14.2.240
160. Lee T, Pelletier J. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter. Physiol Genomics (2001) 7:187-200.
161. Byrne I, Flanagan L, Tenniswood M, Welsh J. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology (2000) 141:2829-36. doi:10.1210/endo.141.8.7618
162. Wietzke J, Warda E, Schneider J, Welsh J. Regulation of the human Vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites. Mol Cell Endocrinol (2005) 230:59-68. doi:10.1016/j.mce.2004.11.001
163. Tolhuis B, Palstra R, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell (2002) 10:1453-65. doi:10.1016/S1097-2765(02)00781-5